Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

MicroREvolution - a high-throughput drop-based microfluidic platform for rapid screening of highly diverse antimicrobial peptide mutant libraries generated via directed evolution.

Descrizione del progetto

Evoluzione in vitro di nuovi peptidi antimicrobici

La resistenza agli antibiotici rappresenta una notevole minaccia per la salute globale, poiché interessa il trattamento di molte infezioni e ostacola il successo di interventi chirurgici e procedure ospedaliere di routine. I peptidi antimicrobici sono emersi come candidati promettenti per affrontare le infezioni; essi fanno parte del meccanismo di difesa dell’ospite e uccidono i batteri inducendo danni alla membrana cellulare. Il progetto MicroREvolution, finanziato dall’UE, riconosce il potenziale terapeutico dei peptidi antimicrobici e propone di usare approcci basati sull’evoluzione diretta per contrastare qualsiasi effetto collaterale indesiderato degli stessi. I ricercatori svilupperanno una piattaforma ad alte prestazioni basata sulla microfluidica per esplorare rapidamente il potenziale terapeutico di peptidi antimicrobici geneticamente diversi che possono possedere caratteristiche migliorate.

Obiettivo

The extensive overuse of antibiotics in both the medicine and food industry resulted in the emergence of multidrug-resistant bacteria strains, putting at risk lives of millions of patients worldwide. Finding new antibiotics is a highly challenging and continuous process, as, eventually, bacteria develop resistance for specific antibiotic(s). Thus, there is an urgent need for alternative long-lasting antimicrobial agents.
Antimicrobial peptides (AMPs) are a part of the innate host defence system that counteract microbial infections. AMPs exhibit a rapid antimicrobial activity covering both Gram-positive and Gram-negative bacteria. Due to this feature, AMPs are very appealing as potential pharmacological agents that could be used as an alternative for conventional antibiotics. Although many AMPs show high antibacterial activity, they also exhibit undesirable characteristics that prevent their widespread implementation in clinical use. In nature, development of biomolecules is driven by evolution, which can be mimicked in the laboratory using directed evolutionary processes to generate billions of variations of genetic sequences that encode myriad peptides or proteins some of which possess improved characteristics. One of the main experimental challenges in directed evolution studies is the relatively large size of the DNA-encoded libraries that must be screened. In the context of AMP evolution studies, an additional challenge is the time-consuming nature of the conventional assays used to assess the antimicrobial activity of AMPs.
Here, I propose establishing MicroREvolution as a novel high-throughput microfluidics-based platform that will overcome limitations of current conventional assays and realise a novel concept, offering an exceptional possibility to rapidly explore the therapeutic potential of myriad laboratory-evolved AMPs in a time- and cost-effective manner.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2020

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Contributo netto dell'UE
€ 212 933,76
Indirizzo
TRINITY LANE THE OLD SCHOOLS
CB2 1TN CAMBRIDGE
Regno Unito
Regione
East of England East Anglia Cambridgeshire CC
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 212 933,76